Wegovy 7.2mg is an upcoming higher-strength dose of Wegovy (semaglutide) that has been announced for future release. This new dose is designed for patients who may require additional appetite suppression and weight-loss support beyond the current maximum 2.4mg maintenance dose. Wegovy 7.2mg is not yet available in the UK and will be offered subject to regulatory approval and prescribing guidance.
Wegovy 7.2mg is a higher-dose formulation of semaglutide, the same active ingredient used in existing Wegovy injections. Like current Wegovy doses, it is intended to be used as part of a structured weight-management programme alongside dietary changes and increased physical activity. The higher dose may offer an additional option for patients who do not achieve sufficient appetite control at lower maintenance doses.
Some patients experience reduced effectiveness over time or require stronger appetite suppression to maintain weight loss. Wegovy 7.2mg has been developed to address this need by providing a higher-strength option for suitable patients under medical supervision. Clinical development is focused on improving long-term weight-loss outcomes while maintaining safety and tolerability.
Wegovy 7.2mg is not currently available in the UK. The dose has been announced but is still subject to regulatory approval, prescribing guidance, and supply availability. Once approved, Wegovy 7.2mg would be prescribed only following a medical assessment by a qualified prescriber.
If approved, Wegovy 7.2mg may be considered for adults who have already progressed through standard Wegovy dosing and require additional support for appetite control and weight management. Suitability would depend on individual medical history, response to treatment, and tolerance of semaglutide.
Current Wegovy treatment typically progresses up to a maintenance dose of 2.4mg. Wegovy 7.2mg would represent a significant increase in dose strength and would not replace existing dosing schedules. Instead, it may provide an alternative option for selected patients under specialist prescribing guidance.
Mounjaro currently offers higher maximum dosing through its dual-action formulation. Wegovy 7.2mg may narrow the gap for patients seeking a higher-dose GLP-1 option once it becomes available. Direct comparisons, pricing, and prescribing criteria will be clearer following official UK release.
If approved in the UK, Wegovy 7.2mg is expected to be available via private prescription following a medical consultation. Availability through the NHS would depend on national and local commissioning decisions. Patients seeking earlier access typically choose private treatment routes.
This page will be updated as soon as further information becomes available regarding UK approval, prescribing criteria, and availability of Wegovy 7.2mg. In the meantime, patients can begin or continue treatment with existing Wegovy doses through a private medical consultation.
If you are considering Wegovy for weight loss, you can complete an online consultation to check your eligibility for current Wegovy doses. If approved, your treatment will be prescribed by a UK-registered doctor and dispensed by a UK pharmacy.
